SHR 6390

Drug Profile

SHR 6390

Alternative Names: SHR 6390

Latest Information Update: 21 Apr 2016

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma

Most Recent Events

  • 19 Feb 2016 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Late-stage disease) in China (NCT02684266)
  • 01 Jan 2016 Phase-I clinical trials in Malignant melanoma (Late-stage disease, Inoperable/Unresectable) in China (PO) (NCT02671513)
  • 30 Dec 2015 Preclinical trials in Malignant melanoma in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top